{
    "title": "Antineoplaston Therapy",
    "inventor_name": "Stanislaw Burzynski",
    "publication_year": null,
    "device_name": "Antineoplaston Therapy",
    "goal": "Treat cancer by inhibiting oncogenes, promoting apoptosis, and activating tumor-suppressor genes.",
    "problem_addressed": "Various cancers and chemotherapy-induced fatigue/toxicity.",
    "concept_summary": "Antineoplastons are a group of peptide-derived compounds (e.g., A-10, AS2-1, phenylacetylglutamine) administered intravenously or orally to cancer patients. The therapy claims anti-cancer activity by modulating oncogenic pathways, DNA-methylation enzymes, and histone deacetylases. Formulations include plain mixtures and liposomal delivery systems that allegedly increase cellular uptake and antineoplastic potency.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Peptide-based drug therapy",
        "Oncogene inhibition",
        "Apoptosis induction",
        "Tumor-suppressor gene activation",
        "Histone deacetylase (HDAC) inhibition",
        "Liposomal drug delivery"
    ],
    "scientific_domains": [
        "Medicine",
        "Pharmacology",
        "Biochemistry"
    ],
    "mechanisms_of_action": [
        "Inhibition of oncogenic enzymes",
        "Promotion of programmed cell death",
        "Activation of p21 and p53 tumor-suppressor pathways",
        "Weak inhibition of HDAC by phenylacetic acid",
        "Alteration of DNA-methylation enzyme activity"
    ],
    "materials": [
        "Phenylacetylglutamine",
        "Phenylacetic acid",
        "Phenylacetylisoglutamine",
        "Phenylbutyrate",
        "Riboflavin",
        "Essential and non-essential amino acids",
        "Silica (as abrasive in toothpaste formulation)",
        "Liposome carriers"
    ],
    "energy_sources": [],
    "inputs": [
        "Patient (cancer diagnosis)",
        "Antineoplaston compounds (A-10, AS2-1, etc.)",
        "Intravenous pump (for continuous infusion)",
        "Oral formulation"
    ],
    "outputs": [
        "Reduction of tumor growth",
        "Mitigation of chemotherapy-induced fatigue",
        "Potential remission of neoplastic disease"
    ],
    "claimed_performance": "Liposomal formulations increase in-vitro antineoplastic activity by a factor of 750-1500 and cellular uptake by 30-80-fold compared with non-liposomal antineoplastons.",
    "experimental_evidence": "Laboratory studies have shown inhibition of DNA-methylation enzymes and weak HDAC inhibition; however, independent tests at the National Cancer Institute and the Japanese National Cancer Institute reported no positive anti-cancer effects.",
    "replication_status": "No independent replication of clinical efficacy reported.",
    "keywords": [
        "Antineoplaston",
        "Cancer therapy",
        "Peptide drug",
        "Liposomal delivery",
        "HDAC inhibitor",
        "Clinical trial"
    ],
    "related_technologies": [
        "Conventional chemotherapy",
        "Targeted molecular therapy",
        "Liposomal drug delivery systems"
    ],
    "controversy_level": "high",
    "confidence_score": 0.6,
    "practicability_score": 0.4,
    "fringe_score": 0.7,
    "evidence_strength": 0.3,
    "risk_score": 0.5,
    "trl_estimate": 3,
    "source_urls": [
        "http://en.wikipedia.org/wiki/Antineoplaston",
        "http://www.burzynskiclinic.com/"
    ],
    "organizations": [
        "Burzynski Clinic",
        "Burzynski Company"
    ],
    "applications": [
        "Cancer treatment",
        "Alleviation of chemotherapy-induced fatigue"
    ],
    "limitations": [
        "Not FDA-approved",
        "High treatment cost (> $100,000 per year)",
        "Lack of peer-reviewed positive clinical data",
        "Potential sodium overload requiring careful electrolyte management"
    ],
    "open_questions": [
        "Does antineoplaston therapy provide statistically significant survival benefit?",
        "What is the precise molecular mechanism of action in humans?",
        "Can liposomal formulations be safely scaled for widespread clinical use?"
    ],
    "red_flags": [
        "Independent studies have failed to demonstrate efficacy",
        "Financial conflict of interest (clinic trades as penny stock)",
        "Claims of anti-cancer activity without robust, peer-reviewed data"
    ],
    "evidence_quotes": [
        "Independent tests at the National Cancer Institute have never been positive.",
        "Antineoplastons have been shown in the laboratory to inhibit these enzymes.",
        "Phenylacetic acid contained in the AS2-1 mixture has been shown to be a weak HDAC inhibitor.",
        "Liposomal formulations increase in vitro antineoplastic activity by a factor of 750 to 1500 as compared to administration of antineoplaston compounds given without liposomal formulations."
    ]
}